Coagulation factor VIIa Recombinant Human
- Generic Name
- Coagulation factor VIIa Recombinant Human
- Brand Names
- Niastase RT, Novoseven, Sevenfact, NovoSeven
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 102786-61-8
- Unique Ingredient Identifier
- AC71R787OV
- Background
Recombinant human coagulation Factor VIIa (rFVIIa), intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues. Cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.
- Indication
For treatment of hemorrhagic complications in hemophilia A and B.
- Associated Conditions
- Bleeding, Bleeding caused by Hemophilia A, Bleeding caused by Hemophilia B, Severe Bleeding
- Associated Therapies
- -
Hemophilia B Treatment Market 2034: EMA, PDMA, FDA Approvals
Hemophilia B market to grow significantly by 2034, driven by gene therapies like HEMGENIX and BEQVEZ, priced at $3.5 million each. Key companies include Centessa Pharmaceuticals, Sanofi, Pfizer, and Novo Nordisk. Market dynamics influenced by increasing prevalence, prophylactic treatment focus, and pipeline advancements.
TiumBio doses first participant in Phase II trial of immuno-oncology drug
TiumBio has initiated a Phase II trial of oral immuno-oncology drug TU2218, targeting advanced solid tumours, with the first HNSCC patient dosed. The trial aims to assess TU2218's safety and efficacy in combination with Keytruda for HNSCC, biliary tract, and colorectal cancers. TU2218, a dual inhibitor of TGFR1 and VEGFR2 pathways, seeks to enhance immune checkpoint inhibitor efficacy.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath